Abstract
The CALGB 9633 study was designed to evaluate the efficacy of carboplatin and paclitaxel given in the adjuvant setting to patients with Stage IB non-small-cell lung cancer. Although interim analysis had shown clinical benefit, longer follow-up revealed lack of efficacy for this approach. We will examine the results of this trial in light of other positive adjuvant trials in patients with non-small-cell lung cancer.
Original language | English |
---|---|
Pages (from-to) | 19-22 |
Number of pages | 4 |
Journal | Future Oncology |
Volume | 5 |
Issue number | 1 |
DOIs | |
State | Published - 2009 |
Keywords
- Adjuvant chemotherapy
- Carboplatin
- Lung cancer
- Paclitaxel